What is it about?
Monocytes and macrophages play critical roles in inflammatory and immune responses; therefore, the modulation of their functions is a useful strategy for anti-inflammatory therapies, including nanotherapies. Lipopolysaccharide (LPS) can cause an acute inflammatory response by triggering the release of a vast number of inflammatory cytokines in various cell types, including monocytes/macrophages. Gi proteins mediate LPS effects in monocytes/macrophages. GOT is a potent Gi inhibitor, and reduces inflammation in vascular cells In this study we show that GOT encapsulated in liposomes (Lipo/GOT) blocked inflammatory mediators production by LPS in monocytes/macrophages while free Got showed reduced or no effects..
Featured Image
Why is it important?
Our findings demonstrate the potential of liposome-encapsulated GOT, as a novel nanotherapy to block LPS proinflammatory effects in monocytes/macrophages.
Perspectives
This study has co-authors with whom I have many collaborations on exploring the potential of inflammatory molecules and mechanisms as targets for nanotherapies.
Ileana Manduteanu
Institute of Cellular" Biology and Pathology"Nicolae Simionescu"
Read the Original
This page is a summary of: Lipopolysaccharide-induced inflammation in monocytes/macrophages is blocked by liposomal delivery of Gi-protein inhibitor, International Journal of Nanomedicine, December 2017, Dove Medical Press,
DOI: 10.2147/ijn.s150918.
You can read the full text:
Contributors
The following have contributed to this page
